Eli Lilly announced on May 26, 2026 that it would acquire three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—for up to nearly $4 billion combined. The deals mark a significant expansion into infectious disease vaccines, funded by cash from Eli Lilly's booming GLP-1 business. The three companies are developing shots against pathogens that cause long-term health issues.
Eli Lilly vaccine acquisitions
- ▪The three vaccine developers being acquired by Eli Lilly are Curevo, LimmaTech Biologics, and Vaccine Company
- ▪Eli Lilly announced on May 26, 2026 that Eli Lilly would buy three early- and mid-stage vaccine developers
- ▪The three vaccine developer acquisitions by Eli Lilly could cost up to nearly $4 billion together
- ▪The three vaccine developers being acquired by Eli Lilly are working on shots against pathogens that can cause long-term health issues
GLP-1 revenue fueling deals
- ▪In recent months, Eli Lilly picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each
- ▪Eli Lilly is rich with cash from Eli Lilly's booming GLP-1 business
Story comments
Loading comments…